Vertex Pharmaceuticals Logo

Email this page: News Release

U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis

For security reasons, registration is required before you can use this feature.
* Indicates required field